bluuebunny/crossref_metadata_2025_split huggingface dataset:
High dose systemic methotrexate‐associated acute neurologic dysfunction
Authors: Packer Roger J. , Grossman Robert I. , Belasco Jean Bello 
Published: February 2007

AbstractTwo patients treated with high dose methotrexate with citrovorum rescue (HDMTX‐CF) for osteogenic sarcoma developed the acute onset of neurologic deficits. Prior to the onset of symptoms, one child suffered brief episodes of altered consciousness. Both patients developed hemiparesis and then steadily improved over 72 hours. Laboratory evaluations disclosed normal coagulation parameters and nontoxic serum methotrexate levels at onset of symptoms. Computed tomography in one child disclosed a large low absorption abnormality. This patient represents the first reported case of positive radiologic findings associated with this syndrome. The two patients recovered completely and received further HDMTX‐CF without sequelae. This condition may result from transient demyelination or embolic cerebrovascular disease.
Bone marrow involvement in histiocytosis X
Authors: McClain K. , Ramsay N. K. C. , Robison L. , Sundberg R. D. , Nesbit M. 
Published: February 2007

AbstractTwenty‐eight patients with histiocytosis × (HX) who had bone marrow aspirates and/or trephine biopsies taken at diagnosis were studied. Five of the 28 patients (18%) had bone marrow specimens with clusters of benign histiocytes characteristic of histiocytosis X. Several statistically significant clinical and laboratory differences were found between those patients with postive marrows versus those with uninvolved bone marrows. Presence of HX in the bone marrow was more frequently associated with fever (P < 0.01), splenomegaly (P < 0.01), rash (P = 0.04), diabetes insipidus (P = 0.09), and platelet counts less than 175 × 109/L (P = 0.01). Two of the five patients with bone marrow involvement died, whereas there were no deaths due to HX in the other 23 patients. From this review, it is suggested that bone marrow involvement at diagnosis may be associated with more extensive and potentially fatal disease. HX of the marrow was more easily diagnosed from trephine biopsy sections than aspiration smears.
Case report: Nasopharyngeal rhabdomyosarcoma and gorlin's naevoid basal cell carcinoma syndrome
Authors: Beddis I. R. , Mott M. G. , Bullimore J. 
Published: February 2007

AbstractA 4‐year‐old girl presented with a nasopharyngeal rhabdomyosarcoma and had the characteristic features of the naevoid basal cell carcinoma syndrome. She was treated with a modified standard combination of chemotherapy and radiotherapy. However, radiotherapy had to be interrupted because of severe radiation recall.
Treatment of spinal cord compression: A retrospective analysis
Authors: Loeffler Jay S. , Glicksman Arvin S. , Tefft Melvin , Gelch Melvyn 
Published: February 2007

AbstractEpidural spinal cord compression from metastatic disease is a common neurological complication of cancer. The incidence is probably increasing owing to continual advancements in the treatment of cancer that have led to prolongation of life and a greater probability of secondary involvement of the spinal cord.A problem often encountered by the oncologist treating patients with epidural spinal cord compression is the recurrence of compression by metastatic tumor both in and out of the original treatment field. Radiotherapists are often presented with the difficult task of trying to determine the optimal dose/time fractionation with the hope of improving the therapeutic ratio.We have examined the charts of 80 patients treated at the Rhode Island Hospital during the last five years (1975‐1980) with myelographic evidence of cord compression in order to determine 1) the recurrence rate of cord compression by metastatic tumor after radiotherapy treatment both in and out of the original treatment field; 2) the influence of various dose/fractionation schedules on the disease‐free interval; 3) the percentage of recurrence out of the treatment field that might represent “skipped lesions” at the original time of diagnosis.Our results show 1) that 9 patients (11.3%) experienced recurrence within the original treatment field; 2) that 21 (26.3%) experienced recurrence within the spinal canal, but out of the original treatment field; 3) that 9 of the 21 (42%) cases of recurrence out of the original treatment field occurred within 1 week and thus were determined to be “>Our results show 1) that 9 patients (11.3%) experienced recurrence within the original treatment field; 2) that 21 (26.3%) experienced recurrence within the spinal canal, but out of the original treatment field; 3) that 9 of the 21 (42%) cases of recurrence out of the original treatment field occurred within 1 week and thus were determined to be” at the time of diagnosis; and 4) that there appears to be a dose‐response relationship for those patients treated successfully without recurrences who did not have presenting symptoms of complete paraplegia.
Hypereosinophilic syndrome in acute lymphoblastic leukemia with a chromosome translocation [t(5q;14q)]
Authors: Tono‐oka Tatsuhito , Sato Yoshiko , Matsumoto Takahide , Ueno Norihiro , Ohkawa Masato , Shikano Takaaki , Takeda Takeo 
Published: February 2007

AbstractWe report a case of hypereosinophilic syndrome associated with acute lymphoblastic leukemia (L1 type, FAB classification) which showed an abnormal karyotype. An 8‐year‐old boy was admitted to our hospital with complaints of fever and cough that had persisted for 2 weeks. Peripheral blood examination revealed remarkable eosinophilia (120,000/mm3) and a few lymphoblasts. Bone marrow examination also revealed many mature eosinophils and 20% lymphoblasts that were PAS and peroxidase negative. A direct chromosome analysis of the bone marrow cells demonstrated that 12.5% of the spontaneously dividing cells had an abnormal karyotype of 46XY, t(5;14) (q31;q32). The chest radiogram showed interstitial pneumonia‐like densities, and the ECG had the pattern of a right bundle branch block. The therapy consisted of prednisolone, high dose of methylprednisolone, cyclophosphamide, and vincristine. This treatment failed to reduce the eosinophil count. On the 4th day after admission, the patient developed severe dyspnea, complete A‐V block, and died. At postmortem, dense infiltrations of eosinophils in various stages of maturation were noted in lungs and liver.
Medical student interactions with cancer patients: Evaluation with videotaped interviews
Authors: Terasaki Melanie R. T. , Morgan Clifford O. , Elias Laurence 
Published: February 2007

AbstractIn order to evaluate the impact of a block in cancer medicine upon student interactions with cancer patients, a group of 32 students have been videotaped during interviews with simulated and genuine cancer patients before and after the block. The videotapes were scored and analyzed for frequencies and patterns of interactions by the method of Reciprocal Category Analysis. This disclosed significant decreases in purely factual questions by the students, with corresponding in creases in discussion of emotional aspects of illness, following the course. The temporal pattern of interaction also changed with less of a tendency to delay or avoid addressing emotional aspects of disease noted. In addition to demonstrating changes in student interactions with cancer patients following a didactic course, this study exemplifies an approach offering more direct assessment of physician‐patient interactions than has been practical using questionnaires.
Serum LDH values in childhood acute leukemias and non‐Hodgkin's lymphoma
Authors: Suarez Carlos R. , Andreeff Michael , Miller Denis R. 
Published: February 2007

AbstractSerum lactate dehydrogenase activity (LDH) was examined in 66 children with acute lymphoblastic leukemia (ALL), 26 with acute non‐lymphocytic leukemia (ANLL), and 116 with non‐Hodgkin's lymphoma (NHL). The mean serum LDH value for the ALL and ANLL groups was not significantly different: 970 ± 105 units/L (mean ± standard error of the mean) and 817 ± 161 units/L, respectively. The difference between the LDH values in patients with ALL (970 ± 105 units/L) and NHL (551 ± 51 units/L) was significant (P = .001). In 32% of the patients with ALL and 23% of the patients with ANLL, serum LDH values were above 1000 units/L, whereas only 13% of the cases with NHL had values above 1000 units/L. In patients with ALL the LDH levels were correlated with white blood cell counts at the time of diagnosis. In NHL, there was no difference in serum LDH levels among the various histologic subtypes. Values of LDH in stage IV NHL and in ALL were similar.
Cisplatinum‐induced renal salt wasting
Authors: Kurtzberg Joanne , Dennis Vincent W. , Kinney Thomas R. 
Published: February 2007

AbstractWe report two patients who developed high urinary excretion of sodium chloride after receiving cisplatinum. One patient became symptomatically hyponatremic during intravenous administration of hypotonic fluid. The second patient developed orthostatic hypotension. Urine sodium and chloride concentrations exceeded 130 mmol/liter despite hyponatremia or volume depletion. There was no evidence of adrenal cortical impairment and no improvement with fludrocortisone. We propose that cisplatinum may inhibit solute transport by the thick ascending limb of Henle, causing clinically significant, previously unreported toxicity in patients receiving chronic cisplatinum antitumor therapy.
Effective chemotherapy for metastatic malignant sacrococcygeal tumour
Authors: Beddis I. R. , Noblett Helen , Mott M. G. 
Published: February 2007

AbstractTwo children with disseminated malignant sacrococcygeal tumour were treated with six courses of vinblastine, cis‐platinum, and bleomycin. Both had exploratory operations after four courses of treatment and no histological evidence of malignant disease was found. The two children have remained free of disease with normal α‐fetoprotein levels for 30 months and 18 months, respectively.
Testicular function following combination chemotherapy with Cis‐platin, vinblastine, and bleomycin
Authors: Johnson David H. , Hainsworth John D. , Linde Randolph B. , Greco F. Anthony 
Published: February 2007

AbstractRecovery of the pituitary‐gonadal axis following treatment with vinblastine, bleomycin, cis‐platin ± doxorubicin (VBP ± A) is assessed retrospectively in 18 men with germinal neoplasms. One patient also received VP‐16‐213. In the first year after completing treatment all men demonstrated elevated follicle stimulating hormone (FSH) and luteinizing hormone (LH) values with concomitant azoospermia. Of the 11 men evaluated at least 24 months from completion of therapy, seven (64%) had recovery of both FSH and LH to normal or near normal levels. Spermatogenesis was present in five of six (83%) men providing semen samples and who were at least 2 years from stopping VBP. Five of seven (71%) men who were within 24 months of therapy were azoospermic. Regardless of the time of evaluation, most men (94%) had normal serum testosterone. Patients receiving maintenance vinblastine had more prolonged elevation of serum gonadotropins. We conclude that some men have evidence of recovery of fertility beginning two years after VBP ± A. In addition to germinal epithelium destruction, transient Leydig cell dysfunction occurs but is not accompanied by clinical findings of hypogonadism.
Hodgkin's disease presenting in epitrochlear nodes
Authors: Yu Anthony , Steinfeld Alan D. 
Published: February 2007

AbstractTwo cases of Hodgkin's Disease (HD) presenting in epitrochlear nodes are described, and compared to four similar cases gleaned from the literature. The nodular sclerosis type of HD was present in 5 of the 6 patients. Of the four patients staged with laparotomy, two had infradiaphragmatic disease. A treatment approach using radiation alone for patients with disease limited to the epitroclear region is presented, and anatomical considerations of the treatment technique are given.
Hypopyon in acute lymphoblastic leukemia
Authors: Smith W. Sean , Burke Miles J. , Wong K. Y. 
Published: February 2007

AbstractA child with acute lymphoblastic leukemia had central nervous system relapse 23 months after diagnosis while in bone marrow remission. This was followed by leukemic involvement of the eye as the only site of relapse 7 months later. Leukemic cells layered out in the anterior chamber and cytologic examination was the only way to make a definitive diagnosis of leukemic hypopyon. Topical treatment is generally ineffective and radiotherapy is the treatment of choice. The prognosis with this complication depends on whether it occurs during therapy or after therapy has been discontinued.
Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas
Authors: Edmonson J. H. , Creagan E. T. , Kvols L. K. , Richardson R. L. , Rubin J. , Green S. J. 
Published: February 2007

AbstractFifty‐eight adults with unresectable metastatic sarcomas received monthly courses of bleomycin, cylcophosphamide, doxorubicin, and cisplatin (BCAP) in combination. Following four courses of BCAP, alternating monthly courses of vincristine, cyclophosphamide, dactinomycin and vincristine, doxorubicin, and dacarbazine were begun. Treatment was continued until disease progression or the achievement of disease resectability, with elimination of doxorubicin after a total dose of 520 mg/m2 had been received. Ten patients electively stopped treatment prematurely. One other patient was removed from treatment because of significant pulmonary toxicity. Of the 58 patients 20 (34%) achieved partial regression of disease including 10 of 18 with leiomyosarcoma, 2 of 8 with malignant fibrous histiocytomas, 3 of 8 with osteosarcoma, 3 of 7 with fibrosarcoma, 1 of 2 with epithelioid sarcoma, and 1 of 1 with mesenchymal chondrosarcoma. Median time to disease progression was 174 days and median survival was 341 days. The percentage of patients achieving disease regression on this study was nearly the same as the percentage achieving disease regression on study of CAP in advanced sarcomas.
Continuing medical education with a personalized monthly newsletter
Authors: Love Richard R. , Moorman Jeanne E. 
Published: February 2007

AbstractThe periodic newsletter is an approach to continuing medical education whose value is difficult to measure. A six‐page monthly newsletter covering cancer and ambulatory medicine topics has been developed in two departments of a university medical center to meet perceived educational needs of new regional primary care practitioners and to maintain a helping relationship between university based and practicing physicians. The newsletter is sent free of charge to requesting clinicians. Each issue of the newsletter is introduced by a personalized letter signed individually by the editor. A reader survey was conducted to evaluate the interest of recipients and the content, usefulness, and format of the newsletter. A usable response rate of 76% was achieved. The evaluation documented that most readers found the publication useful in their practices, remembered receiving issues specifically, kept issues themselves after circulation to colleagues, and read the cover letter. Compared with conference or formal journal instructional methods of continuing medical education, a newsletter may consistently reach a larger audience at a fraction of the cost.
Acute transformation of chronic lymphocytic leukemia
Authors: Jacobs Andrew D. , Schroff Robert W. , Gale Robert Peter 
Published: February 2007

AbstractA patient with chronic lymphocytic leukemia had typical cell morphology and a characteristic clinical course for 7 years. He then developed progressive disease with a rapidly rising WBC which proved resistant to chemotherapy. The cells resembled lymphoblasts. Immunoperoxidase studies demonstrated identical immunoglobulin light and heavy chains on the surface of both mature lymphocytes and lymphoblasts. Using a recently described monoclonal antibody, B5, a “blast” antigen was demonstrated on the lymphoblast cell surface, but not on the mature lymphocytes. On the basis of morphological and immunological studies, we suggest that the patient's malignant clone transformed from chronic lymphocytic leukemia to acute lymphoblastic leukemia.
Involved field (IF) irradiation with or without chemotherapy in the management of children with Hodgkin's disease
Authors: Jereb Berta , Tan Charlotte , Bretsky Sara , He Shaoquin , Exelby Philip 
Published: February 2007

AbstractThe present policy at Memorial Sloan Kettering Cancer Center (MSKCC) of treating children with Hodgkin's disease [HD] is as follows: involved field (IF) irradiation only (3,600 rad) for Stages IA and IIA; IF irradiation (2,400 or 2,000 rad) combined with multidrug chemotherapy (MDP) protocol for all other stages. A somewhat higher recurrence rate is accepted for Stages IA and IIA in view of the good salvage rate for these recurrences and in view of side effects of more aggressive types of radiation treatment.One hundred forty‐two patients with HD, 2‐19 years of age, were treated at MSKCC between 1970 and 1981; 98 of these were treated according to the present policy (SP group), and 44 (NP group) were treated differently. All SP patients underwent staging laparotomy. The follow‐up time was 12 to 146 months with a median of 65 months; two patients were lost to follow‐up.For the SP group, all stages, 10‐year disease‐free survival is 77%, and 10‐year survival is 93%. By comparison, in the NP group 10‐year disease‐free survival is 64%, and 10‐year survival is 80%. The disease‐free survival of SP patients in Stages IA and IIA treated with IF radiation alone is 72%, and survival is 95%. The disease‐free survival of SP patients in advanced stages treated with combined radiation and chemotherapy is 87%; the salvage rate of recurrent disease in these stages is poor. The survival was apparently better (P = 0.07) in the SP group as compared to the NP group. All 6 patients of the SP group who died had a nodular sclerosing type of HD. None of the patients in the SP group have developed secondary malignancies, and no severe bone growth retardations or late effects to other organs were observed.In our opinion, IF irradiation alone might at present be suitable treatment for children in Stages IA and IIA of Hodgkin's disease, and addition of IF radiation with low doses of MPD improves the survival of patients in advanced stages.
Recurrent testicular infiltrates following radiation therapy for lymphoid malignancy
Authors: Blatt Julie , Wollman Michael R. , Albo Vincent C. , Orlando Salvatore , Silverman Craig L. 
Published: February 2007

AbstractFrom a group of 28 patients with biopsy‐proven testicular leukemia seen at our institution since 1979, we describe two boys with lymphoid malignancy who, subsequent to 1,800 rad and 2,400 rad testicular radiation, had second overt testicular relapses. This experience suggests that these patients need careful follow‐up physical examinations, that higher doses may be needed for prolonged local control, and that there may be a role for follow‐up testicular biopsies.
Retinoblastoma, eosinophilic granuloma, and malignant melanoma: A case report
Authors: Casson A. G. , Maroun F. B. , Arnold A. M. , Newman C. E. 
Published: February 2007

AbstractThe case history of a patient treated for unilateral hereditary retinoblastoma who subsequently developed malignant melanoma and eosinophilic granuloma is presented. Although the association between retinoblastoma and second malignancies including malignant melanoma is established, we have found no reports of third malignancies occurring in such individuals.
Racial variation in incidence of Wilms' tumor: Relationship to congenital anomalies
Authors: Kramer Shira , Meadows Anna T. , Jarrett Patricia 
Published: February 2007

AbstractThis is a study of the occurrence of Wilms' tumor and associated anomalies in all incident cases in the Greater Delaware Valley by race. The average annual incidence of Wilms' tumor in this population of 2 million children is significantly higher among nonwhites than whites. A significantly larger proportion of black cases has a Wilms' tumor‐associated condition including aniridia, genito‐urinary anomalies, the Beckwith‐Wiedemann Syndrome, and hemihypertrophy. For very young patients, there was a greater tendency for blacks to have bilateral tumors or a tumor‐associated anomaly, features characteristic of the hereditary form of Wilms' tumor. The excess risk of Wilms' tumor among blacks may be a result of a higher proportion having a hereditary predisposition or more common exposure to agents capable of inducing germinal mutations.
Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma
Authors: Harvey J. , Bonnem E. , Grady K. , Goodman A. , Schein P. 
Published: February 2007

AbstractFourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a 4‐day rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or complete responses. This study failed to confirm the previously reported therapeutic activity of this agent in colorectal carcinoma, using an identical dose and schedule. We have initiated a phase I study of daunorubicin to identify a maximum tolerated dose using an every 3‐week schedule for future phase II trials in solid tumors.
Role of radionuclide imaging in the diagnosis of chondrosarcoma
Authors: McLean Richard G. , Choy Daniel , Höschl Radmil , Nayanar Vimala , Murray I. Provan C. 
Published: February 2007

AbstractThe diagnosis of chondrosarcoma may be difficult if there is an atypical radiographic appearance or an inconclusive biopsy. Radionuclide bone scans of 13 patients with chondrosarcoma were reviewed to assess if a pattern of scan features could be recognised in association with this tumour. A combination, including increased blood pool activity, moderate intensity of uptake, patchy uptake with cortical predominance of activity, minimal distortion of bony outline, and a well‐defined scintigraphic margin, occurred regularly in the series. Recognition of this characteristic pattern of scintigraphic features in cases of suspected chondrosarcoma may assist in the diagnostic assessment.
Vindesine and high‐dose cisplatin in the treatment of advanced non‐small‐cell lung cancer
Authors: Fuks Joachim Z. , Patel Halesh , van Echo David A. , Hornedo Javier , Aisner Joseph 
Published: February 2007

AbstractSeventeen patients with advanced non‐small‐cell lung cancer (NSCLC) were entered on a combination chemotherapy protocol including vindesine and high‐dose cisplatin. All patients had measurable disease and had not previously received chemotherapy. All patients entered were evaluable for toxicity and response. Tumor regression was limited to one complete and one partial response (response rate, 11.7%; 95% confidence limits, 0 to 27%). The complete and partial response lasted 260 + and 82 days, respectively. For the 15 nonresponding patients, the median time to disease progression was 76 days. Median survival was 141 days for the whole group. Significant toxic effects were vindesine‐related peripheral neuropathy and cisplatin‐in‐duced emesis. Myelosuppression was mild and manageable. The response for the vindesine‐cisplatin combination observed in our study is inferior to that seen in a previous vindesine‐cisplatin trial reported by others. Thus, the true value of this two‐drug regimen in the treatment of NSCLC remains to be established.
Benign metastatic islet cell tumour of the pancreas
Authors: Lewis M. A. , Lilleyman J. S. , Variend S. 
Published: February 2007

AbstractA nine‐year‐old girl was fortuitously found to have a symptomless metastatic islet cell tumour (apudoma) of the head of the pancreas, the first to be described in a child. The tumour has not changed in size over 3 years and the patient has shown normal growth and development. Initial chemotherapy had no effect.